Aktienanalyse zu Accuray Incorporated (ARAY)ARAYAccuray Incorporated

Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells and supports solutions that are designed to deliver radiation treatments for complex cases. Its solutions are designed to advance patient care: during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, it also provides services, which include post-contract customer support (warranty period services and post-warranty services), installation services, training, and other professional services. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Accuray Inc is not a good buy right now due to significant financial losses and poor technical indicators. The current price is $0.1099, and the company has a negative net income of $19.41 million in the last quarter, indicating ongoing financial struggles. Additionally, the RSI is at 22.909, suggesting the stock is oversold, but this does not guarantee a price rebound. The main risk is a high debt-to-equity ratio of 354.61%, which raises concerns about financial stability.

6 analysts cover ARAY: 2 rate it Buy, 3 Hold and 1 Sell. The average price target is 2.00.